Diabetic nephropathy induced by increased ace gene dosage is associated with high renal levels of angiotensin (1-7) and bradykinin

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Bertoncello, Nádia ^a   Moreira, Roseli Peres ^a   Arita, Danielle Yuri ^a   Aragão, Danielle S ^a   Watanabe, Ingrid Kazue Mizuno ^a   Dantas, Patricia S ^a   Santos, Ralmony ^a   Mattar Rosa, Rodolfo ^a   Yokota, Rodrigo ^a   Cunha, Tatiana Sousa ^a   Casarini, Dulce Elena ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN (1-7); ANGIOTENSIN II; BRADYKININ; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT;

ACE GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; INDEL MUTATION; KIDNEY STRUCTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYNTHESIS; ANALYSIS; ANIMAL; BODY WEIGHT; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; METABOLISM; SPECTROFLUOROMETRY;

ANGIOTENSIN I; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; KIDNEY; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SPECTROMETRY, FLUORESCENCE;

EID: 84942279321     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/674047     Document Type: Article

References (79)

1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 2013.
2. The United States Renal Data System (USRDS), Atlas of Chronic Kidney Disease and End-Stage Renal Disease in theUnited States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2013.
3. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi, "End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions, " The American Journal of Kidney Diseases, vol. 34, no. 5, pp. 795-808, 1999.
4. H. Kobori, M. Kamiyama, L. M. Harrison-Bernard, and L. G. Navar, "Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy, " Journal of Investigative Medicine, vol. 61, no. 2, pp. 256-264, 2013.
5. S. B. Gurley and T. M. Coffman, "The renin-angiotensin system and diabetic nephropathy, " Seminars in Nephrology, vol. 27, no. 2, pp. 144-152, 2007.
6. D. J. Leehey, A. K. Singh, N. Alavi, and R. Singh, "Role of angiotensin II in diabetic nephropathy, " Kidney International Supplements, vol. 77, pp. S93-S98, 2000.
7. S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells, " Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431-2437, 1994.
8. J. F. Giani, M. C. Munoz, R. A. Pons et al. , "Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats, " The American Journal of Physiology-Renal Physiology, vol. 300, no. 1, pp. F272-F282, 2011.
9. N. Hayashi, K. Yamamoto, M. Ohishi et al. , "The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells, " Hypertension Research, vol. 33, no. 11, pp. 1182-1185, 2010.
10. Z. Su, J. Zimpelmann, and K. D. Burns, "Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells, " Kidney International, vol. 69, no. 12, pp. 2212-2218, 2006.
11. J. Zhang, N. A. Noble, W. A. Border, and Y. Huang, "Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis, " The American Journal of Physiology-Renal Physiology, vol. 298, no. 3, pp. F579-F588, 2010.
12. J.-Y. Moon, M. Tanimoto, T. Gohda et al. , "Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice, " The American Journal of Physiology-Renal Physiology, vol. 300, no. 6, pp. F1271-F1282, 2011.
13. J. Zimpelmann and K. D. Burns, "Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells, " The American Journal of Physiology-Renal Physiology, vol. 296, no. 2, pp. F337-F346, 2009.
14. V. Esteban, S. Heringer-Walther, A. Sterner-Kock et al. , "Angiotensin-(1-7) and the G protein-coupled receptorMas are key players in renal inflammation, " PLoS ONE, vol. 4, no. 4, Article ID e5406, 2009.
15. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, andD. I. Diz, "Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction, "The American Journal of Physiology-Heart andCirculatory Physiology, vol. 292, no. 1, pp. H666-H672, 2007.
16. Y. Shao, M. He, L. Zhou, T. Yao, Y. Huang, and L.-M. Lu, "Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury, " Acta Pharmacologica Sinica, vol. 29, no. 7, pp. 829-837, 2008.
17. A. Tavares, "Polimorfismos dos genes do sistema reninaangiotensina-aldosterona e as moleculas cardiovasculares, " Revista Brasileira deHipertensao, vol. 7, no. 3, pp. 237-242, 2000.
18. T. S. Ahluwalia, M. Ahuja, T. S. Rai et al. , "ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy, "DNA and Cell Biology, vol. 28, no. 3, pp. 141-150, 2009.
19. S. Rudberg, L. M. Rasmussen, H.-J. Bangstad, and R. Osterby, "Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria, " Diabetes Care, vol. 23, no. 4, pp. 544-548, 2000.
20. J. H. Krege, H.-S. Kim, J. S. Moyer et al. , "Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis, " Hypertension, vol. 29, no. 1, part 2, pp. 150-157, 1997.
21. W. Huang, Y. Gallois, N. Bouby et al. , "Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13330-13334, 2001.
22. J. H. Krege, S. W. M. John, L. L. Langenbach et al. , "Male-female differences in fertility and blood pressure in ACE-deficient mice, " Nature, vol. 375, no. 6527, pp. 146-148, 1995.
23. E. M. Oliveira, R. A. S. Santos, and J. E. Krieger, "Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats, " Brazilian Journal ofMedical andBiological Research, vol. 33, no. 7, pp. 755-764, 2000.
24. M. M. Bradford, "A rapid and sensitive method for the quantitation ofmicrogramquantities of protein utilizing the principle of protein-dye binding, " Analytical Biochemistry, vol. 72, no. 1-2, pp. 248-254, 1976.
25. D. B. Vidotti, D. E. Casarini, P. C. Cristovam, C. A. Leite, N. Schor, andM. A. Boim, "High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells, " The American Journal of Physiology-Renal Physiology, vol. 286, no. 6, pp. F1039-F1045, 2004.
26. F. A. Mendelsohn and C. I. Johnston, "A radiochemical renin assay, " Biochemical Journal, vol. 121, no. 2, pp. 241-244, 1971.
27. J. Friedland and E. Silverstein, "A sensitive fluorimetric assay for serum angiotensin converting enzyme, " The American Journal of Clinical Pathology, vol. 66, no. 2, pp. 416-424, 1976.
28. F. A. Ronchi, M.-C. Irigoyen, and D. E. Casarini, "Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus, " Journal of the Renin-Angiotensin-Aldosterone System, vol. 8, no. 1, pp. 34-41, 2007.
29. K. B. Pedersen, S. Sriramula, K. H. Chhabra, H. Xia, and E. Lazartigues, "Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays, " The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 301, no. 5, pp. R1293-R1299, 2011.
30. H.-L. Tian, L.-S. Wei, Z.-X. Xu, R.-T. Zhao, D.-L. Jin, and J.-S. Gao, "Correlations between blood glucose level and diabetes signs in streptozotocin-induced diabetic mice, " Global Journal of Pharmacology, vol. 4, no. 3, pp. 111-116, 2010.
31. C. Tikellis, C. I. Johnston, J. M. Forbes et al. , "Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy, " Hypertension, vol. 41, no. 3, pp. 392-397, 2003.
32. R. J. Falk, J. I. Scheinman, S. M. Mauer, and A. F. Michael, "Polyantigenic expansion of basement membrane constituents in diabetic nephropathy, " Diabetes, vol. 32, supplement 2, pp. 34-39, 1983.
33. D. Zhu, Y. Kim, M. W. Steffes, T. J. Groppoli, R. J. Butkowski, and S. M. Mauer, "Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry, " Kidney International, vol. 45, no. 2, pp. 425-433, 1994.
34. S. Adler, "Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy, " Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 1165-1172, 1994.
35. R. J. MacIsaac and G. Jerums, "Diabetic kidney disease with and without albuminuria, " Current Opinion in Nephrology and Hypertension, vol. 20, no. 3, pp. 246-257, 2011.
36. F. S. Evangelista and J. E. Krieger, "Small gene effect and exercise training-induced cardiac hypertrophy in mice: an Ace gene dosage study, " Physiological Genomics, vol. 27, no. 3, pp. 231-236, 2006.
37. J. Wysocki, L. Garcia-Halpin, M. Ye et al. , "Regulation of urinary ACE2 in diabetic mice, " The American Journal of Physiology-Renal Physiology, vol. 305, no. 4, pp. F600-F611, 2013.
38. M. Ye, J. Wysocki, J. William, M. J. Soler, I. Cokic, and D. Batlle, "Glomerular localization and expression of angiotensinconverting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes, " Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 3067-3075, 2006.
39. M. Donoghue, F. Hsieh, E. Baronas et al. , "A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, " Circulation Research, vol. 87, no. 5, pp. E1-E9, 2000.
40. S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, "A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captoprilinsensitive carboxypeptidase, " The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238-33243, 2000.
41. J. L. Zhuo, F. M. Ferrao, Y. Zheng, and X. C. Li, "New frontiers in the intrarenal renin-angiotensin system: a critical review of classical and new paradigms, " Frontiers in Endocrinology, vol. 4, article 166, 2013.
42. M. J. Soler, J. Wysocki, M. Ye, J. Lloveras, Y. Kanwar, and D. Batlle, "ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice, " Kidney International, vol. 72, no. 5, pp. 614-623, 2007.
43. J. Wysocki, M. Ye, M. J. Soler et al. , "ACE and ACE2 activity in diabetic mice, " Diabetes, vol. 55, no. 7, pp. 2132-2139, 2006.
44. C. Tikellis, R. Brown, G. A. Head, M. E. Cooper, and M. C. Thomas, "Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes, " The American Journal of Physiology-Renal Physiology, vol. 306, no. 7, pp. F773-F780, 2014.
45. S. Park, B. J. Bivona, H. Kobori et al. , "Major role for ACEindependent intrarenal ANG II formation in type II diabetes, " TheAmerican Journal of Physiology-Renal Physiology, vol. 298, no. 1, pp. F37-F48, 2010.
46. C. Tikellis, K. Bialkowski, J. Pete et al. , "ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes, " Diabetes, vol. 57, no. 4, pp. 1018-1025, 2008.
47. M. Ye, J. Wysocki, P. Naaz, M. R. Salabat, M. S. LaPointe, and D. Batlle, "Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?" Hypertension, vol. 43, no. 5, pp. 1120-1125, 2004.
48. J. G. Modrall, J. Sadjadi, K. B. Brosnihan et al. , "Depletion of tissue angiotensin-converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides, " Hypertension, vol. 43, no. 4, pp. 849-853, 2004.
49. M. B. Monteiro, D. Senador, W. F. Zhang, M. Morris, and K. M. Elased, "Balance of ACE and ACE2 in diabetes: decreased renal ACE2 activity in hypertensive db/db diabetic mice, " Hypertension, vol. 52, article E91, 2008.
50. M. S. Alghamri, N. M. Weir, M. P. Anstadt, K. M. Elased, S. B. Gurley, and M. Morris, "Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice, " Journal of Cardiovascular Pharmacology andTherapeutics, vol. 18, no. 2, pp. 138-151, 2013.
51. H. Chodavarapu, N. Grobe, H. K. Somineni, E. S. B. Salem, M. Madhu, and K. M. Elased, "Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion, " PLoS ONE, vol. 8, no. 4, Article ID e62833, 2013.
52. G. Y. Oudit, A. M. Herzenberg, Z. Kassiri et al. , "Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis, " The American Journal of Pathology, vol. 168, no. 6, pp. 1808-1820, 2006.
53. J. L. Guy, R. M. Jackson, K. R. Acharya, E. D. Sturrock, N. M. Hooper, and A. J. Turner, "Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence, " Biochemistry, vol. 42, no. 45, pp. 13185-13192, 2003.
54. R. A. S. Santos, A. J. Ferreira, T. Verano-Braga, and M. Bader, "Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system, " Journal of Endocrinology, vol. 216, no. 2, pp. R1-R17, 2013.
55. D. W. Wong, G. Y. Oudit, H. Reich et al. , "Loss of Angiotensinconverting enzyme-2 (Ace2) accelerates diabetic kidney injury, " The American Journal of Pathology, vol. 171, no. 2, pp. 438-451, 2007.
56. S. E. Park, W. J. Kim, S. W. Park et al. , "High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria, " European Journal of Endocrinology, vol. 168, no. 2, pp. 203-210, 2013.
57. H. N. Reich, G. Y. Oudit, J. M. Penninger, J. W. Scholey, and A. M. Herzenberg, "Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease, " Kidney International, vol. 74, no. 12, pp. 1610-1616, 2008.
58. J. A. Colucci, D. Y. Arita, T. S. Cunha et al. , "Renin-angiotensin system may trigger kidney damage inNODmice, " Journal of the Renin-Angiotensin-Aldosterone System, vol. 12, no. 1, pp. 15-22, 2011.
59. C. M. Ferrario, J. Varagic, J. Habibi et al. , "Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 4, pp. H1184-H1192, 2009.
60. B. M. Westwood and M. C. Chappell, "Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney, " Peptides, vol. 35, no. 2, pp. 190-195, 2012.
61. J. Di Salvo, A. Peterson, C. Montefusco, and M. Menta, "Intrarenal conversion of angiotensin I to angiotensin II in the dog, " Circulation Research, vol. 29, no. 4, pp. 398-406, 1971.
62. L. Rosivall, D. F. Rinder, J. Champion, M. C. Khosla, L. G. Navar, and S. Oparil, "Intrarenal angiotensin I conversion at normal and reduced renal blood flow in the dog, " The American Journal of Physiology, vol. 245, no. 3, pp. F408-F415, 1983.
63. J. Genest, M. Cantin, R. Garcia et al. , "Extrarenal angiotensinforming enzymes, " Clinical and Experimental Hypertension A, vol. 5, no. 7-8, pp. 1065-1080, 1983.
64. B. U. Wintroub, L. B. Klickstein, and K. W. K. Watt, "A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II, " The Journal of Clinical Investigation, vol. 68, no. 2, pp. 484-490, 1981.
65. J. Rykl, J. Thiemann, S. Kurzawski et al. , "Renal cathepsin G and angiotensin II generation, " Journal of Hypertension, vol. 24, no. 9, pp. 1797-1807, 2006.
66. H. Urata, "Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease, " Journal of the Renin-Angiotensin-Aldosterone System, vol. 1, no. 2, supplement, pp. S35-S37, 2000.
67. C.-C. Wei, Q. C. Meng, R. Palmer et al. , "Evidence for angiotensin-converting enzyme-and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo, " Circulation, vol. 99, no. 19, pp. 2583-2589, 1999.
68. X. R. Huang, W. Y. Chen, L. D. Truong, and H. Y. Lan, "Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease, " Journal of the American Society of Nephrology, vol. 14, no. 7, pp. 1738-1747, 2003.
69. J. Sadjadi, G. L. Kramer, C.-H. Yu, M. B. Welborn III, M. C. Chappell, and J. G. Modrall, "Angiotensin converting enzymeindependent angiotensin II production by chymase is upregulated in the ischemic kidney in renovascular hypertension, " Journal of Surgical Research, vol. 127, no. 2, pp. 65-69, 2005.
70. P. C. Cristovam, C. P. Arnoni, M. C. C. De Andrade et al. , "ACEdependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells, " Experimental Biology and Medicine, vol. 233, no. 8, pp. 1035-1043, 2008.
71. A. H. J. Danser, M. M. G. Koning, P. J. J. Admiraal, F. H. M. Derkx, P. D. Verdouw, and M. A. D. H. Schalekamp, "Metabolism of angiotensin I by different tissues in the intact animal, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 263, no. 2, part 2, pp. H418-H428, 1992.
72. Y. Uehara, S.-I. Miura, E. Yahiro, and K. Saku, "Non-ACE pathway-induced angiotensin II production, " Current Pharmaceutical Design, vol. 19, no. 17, pp. 3054-3059, 2013.
73. A. R. Christlieb, A. Kaldany, and J. A. DElia, "Plasma renin activity and hypertension in diabetesmellitus, " Diabetes, vol. 25, no. 10, pp. 969-974, 1976.
74. R. N. Re, A. A. MacPhee, and J. T. Fallon, "Specific nuclear binding of angiotensin II by rat liver and spleen nuclei, " Clinical Science, vol. 61, supplement 7, pp. 245s-247s, 1981.
75. R. Singh, A. K. Singh, N. Alavi, and D. J. Leehey, "Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose, " Journal of the American Society of Nephrology, vol. 14, no. 4, pp. 873-880, 2003.
76. J. C. Q. Velez, K. J. Ryan, C. E. Harbeson et al. , "Angiotensin i is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli, " Hypertension, vol. 53, no. 5, pp. 790-797, 2009.
77. A. C. Simoes e Silva, J. S. S. Diniz, R. M. Pereira, S. V. B. Pinheiro, and R. A. S. Santos, "Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1-7) in end-stage renal disease, " Pediatric Research, vol. 60, no. 6, pp. 734-739, 2006.
78. E. Velkoska, R. G. Dean, K. Griggs, L. Burchill, andL. M. Burrell, "Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy, " Clinical Science, vol. 120, no. 8, pp. 335-345, 2011.
79. D. J. Campbell, D. J. Kelly, J. L. Wilkinson-Berka, M. E. Cooper, and S. L. Skinner, "Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats, " Kidney International, vol. 56, no. 1, pp. 211-221, 1999.